Tiragolumab (anti-TIGIT therapy) in combination with atezolizumab (Tecentriq) was approved by the FDA for metastatic NSCLC with high PD-L1 based on promising clinical evidence [101]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.